The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
10:55 AM at September 9: Drs. Hagop Kantarjian and Rob Pieters will debate whether ALL is ready to move away from chemotherapy. SOHO Insider editor, Elias Jabbour, MD, explores what the evidence shows in this preview.
Doris K. Hansen, MD, will lead an MTP session on immunotherapy trials at 8 am on September 9.
4:50 PM on September 9: Drs. Amir Fathi and Christian Recher debate whether low-intensity therapy is appropriate for younger patients with AML
Jessy Thomas, PharmD, of Geron Corporation, and colleagues presented the findings at the 2026 SOHO Annual Meeting.
At the same time, emerging results from lower-risk MDS studies raise the possibility that earlier intervention could alter the natural history of the disease. In the COMMANDS trial, luspatercept produced higher and more durable rates of transfusion independence than epoetin alfa.
The conversation covers how funding organizations support the international MDS research community by deploying flexible financial resources, offering faculty transition awards to build the scientific pipeline, and providing Discovery Research Grants to advance individual projects.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
